Overview

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University
Treatments:
Gemcitabine
Oxaliplatin